Kos Selects Advicor(TM) As Brand Name for Pending Lipid-Altering Drug

Apr 18, 2001, 01:00 ET from Kos Pharmaceuticals, Inc.

    MIAMI, April 18 /PRNewswire/ -- Kos Pharmaceuticals, Inc. (Nasdaq:   KOSP)
 announced today that it has selected the brand name Advicor(TM) for its new
 Niaspan(R)/lovastatin combination product, currently being reviewed by the FDA
 for the treatment of dyslipidemia, or multiple lipid disorders.  The
 Advicor(TM) combination product, formerly known as Nicostatin, is expected to
 be cleared for marketing in the second half of this year.
     Advicor(TM) is a unique and proprietary single-tablet formulation of
 Niaspan (extended-release niacin) and lovastatin, which is among the class of
 cholesterol-reducing drugs known as HMG CoA reductase inhibitors or "statins."
 Advicor(TM) was developed by Kos Pharmaceuticals and if cleared by the FDA,
 would be the first combination drug approved for the treatment of
 dyslipidemia.  Advicor(TM) was developed to offer physicians a convenient
 once-daily tablet that combines the effectiveness of a statin in reducing LDL,
 or "bad," cholesterol with the efficacy of Niaspan for improving HDL, or
 "good," cholesterol, and triglycerides.  Advicor(TM) has been studied in more
 than 1,200 patients in numerous clinical studies.
     Millions of adults suffer from multiple lipid risk factors, including not
 only elevated LDL cholesterol, but also abnormal levels of HDL cholesterol,
 triglycerides and Lp(a), an emerging lipid risk factor.  Lipid research has
 shown that such multiple lipid risk factors contribute to coronary heart
 disease, which remains the world's leading cause of death.  Many leading lipid
 researchers believe that in order to thwart the growing incidence of heart
 disease, physicians must aggressively treat multiple lipid risk factors with a
 combination of cholesterol therapies.
     In May 2000, Kos established a co-promotion and co-development agreement
 with DuPont Pharmaceuticals Company to market Advicor(TM).  Both companies
 currently promote cardiovascular therapies, so the arrangement is expected to
 yield increased awareness for Advicor(TM) among physicians prescribing such
 cardiovascular medicines.  The existing market for cholesterol therapies, one
 of the fastest growing multi-billion dollar markets within the pharmaceutical
 industry, is currently growing in excess of 20% annually and now exceeds
 $8 billion in the United States.  Based on FDA clearance, Kos and DuPont are
 expected to jointly launch Advicor(TM) during the first quarter of 2002.
     Niaspan is Kos Pharmaceuticals' proprietary once-daily niacin formulation
 for the treatment of cholesterol disorders.  Kos Pharmaceuticals, Inc. is a
 fully integrated specialty pharmaceutical company engaged in developing and
 commercializing proprietary prescription pharmaceutical products, primarily
 for the treatment of chronic cardiovascular and respiratory diseases.  Kos has
 drug delivery capabilities in both solid-dose and aerosolized formulation
 technologies.
 
     Certain statements in this press release, including statements relating to
 the timing of the FDA's expected clearance of Advicor(TM) and the expected
 launch of Advicor(TM), are forward-looking and are subject to risks and
 uncertainties.  These risks and uncertainties include the Company's ability to
 meet the conditions necessary to obtain funding under its funding
 arrangements, including payments from DuPont, the timing for the development
 and approval of Advicor(TM), the ability of both Kos and DuPont to build
 awareness for Advicor(TM) within the medical community, the continuation of
 Kos' partnership arrangements with DuPont, the effect of conditions in the
 pharmaceutical industry and the economy in general, as well as certain other
 risks.  A more detailed discussion of risks attendant to the forward-looking
 statements included in this press release is set forth in the "Forward-Looking
 Information: Certain Cautionary Statements" section of the Company's Annual
 Report on Form 10-K for the period ended December 31, 2000, filed with the
 Securities and Exchange Commission, and in other reports filed with the SEC.
 
 

SOURCE Kos Pharmaceuticals, Inc.
    MIAMI, April 18 /PRNewswire/ -- Kos Pharmaceuticals, Inc. (Nasdaq:   KOSP)
 announced today that it has selected the brand name Advicor(TM) for its new
 Niaspan(R)/lovastatin combination product, currently being reviewed by the FDA
 for the treatment of dyslipidemia, or multiple lipid disorders.  The
 Advicor(TM) combination product, formerly known as Nicostatin, is expected to
 be cleared for marketing in the second half of this year.
     Advicor(TM) is a unique and proprietary single-tablet formulation of
 Niaspan (extended-release niacin) and lovastatin, which is among the class of
 cholesterol-reducing drugs known as HMG CoA reductase inhibitors or "statins."
 Advicor(TM) was developed by Kos Pharmaceuticals and if cleared by the FDA,
 would be the first combination drug approved for the treatment of
 dyslipidemia.  Advicor(TM) was developed to offer physicians a convenient
 once-daily tablet that combines the effectiveness of a statin in reducing LDL,
 or "bad," cholesterol with the efficacy of Niaspan for improving HDL, or
 "good," cholesterol, and triglycerides.  Advicor(TM) has been studied in more
 than 1,200 patients in numerous clinical studies.
     Millions of adults suffer from multiple lipid risk factors, including not
 only elevated LDL cholesterol, but also abnormal levels of HDL cholesterol,
 triglycerides and Lp(a), an emerging lipid risk factor.  Lipid research has
 shown that such multiple lipid risk factors contribute to coronary heart
 disease, which remains the world's leading cause of death.  Many leading lipid
 researchers believe that in order to thwart the growing incidence of heart
 disease, physicians must aggressively treat multiple lipid risk factors with a
 combination of cholesterol therapies.
     In May 2000, Kos established a co-promotion and co-development agreement
 with DuPont Pharmaceuticals Company to market Advicor(TM).  Both companies
 currently promote cardiovascular therapies, so the arrangement is expected to
 yield increased awareness for Advicor(TM) among physicians prescribing such
 cardiovascular medicines.  The existing market for cholesterol therapies, one
 of the fastest growing multi-billion dollar markets within the pharmaceutical
 industry, is currently growing in excess of 20% annually and now exceeds
 $8 billion in the United States.  Based on FDA clearance, Kos and DuPont are
 expected to jointly launch Advicor(TM) during the first quarter of 2002.
     Niaspan is Kos Pharmaceuticals' proprietary once-daily niacin formulation
 for the treatment of cholesterol disorders.  Kos Pharmaceuticals, Inc. is a
 fully integrated specialty pharmaceutical company engaged in developing and
 commercializing proprietary prescription pharmaceutical products, primarily
 for the treatment of chronic cardiovascular and respiratory diseases.  Kos has
 drug delivery capabilities in both solid-dose and aerosolized formulation
 technologies.
 
     Certain statements in this press release, including statements relating to
 the timing of the FDA's expected clearance of Advicor(TM) and the expected
 launch of Advicor(TM), are forward-looking and are subject to risks and
 uncertainties.  These risks and uncertainties include the Company's ability to
 meet the conditions necessary to obtain funding under its funding
 arrangements, including payments from DuPont, the timing for the development
 and approval of Advicor(TM), the ability of both Kos and DuPont to build
 awareness for Advicor(TM) within the medical community, the continuation of
 Kos' partnership arrangements with DuPont, the effect of conditions in the
 pharmaceutical industry and the economy in general, as well as certain other
 risks.  A more detailed discussion of risks attendant to the forward-looking
 statements included in this press release is set forth in the "Forward-Looking
 Information: Certain Cautionary Statements" section of the Company's Annual
 Report on Form 10-K for the period ended December 31, 2000, filed with the
 Securities and Exchange Commission, and in other reports filed with the SEC.
 
 SOURCE  Kos Pharmaceuticals, Inc.